LHCGR
Lutropin-choriogonadotropic hormone receptor
Also known as: HHG, LCGR, LGR2, LHR, LSHR_HUMAN, ULG5
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P22888
- Gene
- LHCGR
- Ensembl
- ENSG00000138039
- Chromosome
- 2
- Canonical length
- 699 aa
- Protein class
- Disease related genes, FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins
- Subcellular location
- Plasma membrane,Centriolar satellite
OverviewNCBI Gene
This gene encodes the receptor for both luteinizing hormone and choriogonadotropin. This receptor belongs to the G-protein coupled receptor 1 family, and its activity is mediated by G proteins which activate adenylate cyclase. Mutations in this gene result in disorders of male secondary sexual character development, including familial male precocious puberty, also known as testotoxicosis, hypogonadotropic hypogonadism, Leydig cell adenoma with precocious puberty, and male pseudohermaphtoditism with Leydig cell hypoplasia. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
699 residues, UniProt reviewed canonical sequence.
>P22888|LHCGR
1 MKQRFSALQL LKLLLLLQPP LPRALREALC PEPCNCVPDG ALRCPGPTAG LTRLSLAYLP
61 VKVIPSQAFR GLNEVIKIEI SQIDSLERIE ANAFDNLLNL SEILIQNTKN LRYIEPGAFI
121 NLPRLKYLSI CNTGIRKFPD VTKVFSSESN FILEICDNLH ITTIPGNAFQ GMNNESVTLK
181 LYGNGFEEVQ SHAFNGTTLT SLELKENVHL EKMHNGAFRG ATGPKTLDIS STKLQALPSY
241 GLESIQRLIA TSSYSLKKLP SRETFVNLLE ATLTYPSHCC AFRNLPTKEQ NFSHSISENF
301 SKQCESTVRK VNNKTLYSSM LAESELSGWD YEYGFCLPKT PRCAPEPDAF NPCEDIMGYD
361 FLRVLIWLIN ILAIMGNMTV LFVLLTSRYK LTVPRFLMCN LSFADFCMGL YLLLIASVDS
421 QTKGQYYNHA IDWQTGSGCS TAGFFTVFAS ELSVYTLTVI TLERWHTITY AIHLDQKLRL
481 RHAILIMLGG WLFSSLIAML PLVGVSNYMK VSICFPMDVE TTLSQVYILT ILILNVVAFF
541 IICACYIKIY FAVRNPELMA TNKDTKIAKK MAILIFTDFT CMAPISFFAI SAAFKVPLIT
601 VTNSKVLLVL FYPINSCANP FLYAIFTKTF QRDFFLLLSK FGCCKRRAEL YRRKDFSAYT
661 SNCKNGFTGS NKPSQSTLKL STLHCQGTAL LDKTRYTECLocalizationUniProt · AlphaFold · HPA
Whether an antibody against LHCGR can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 7
- Mean surface accessibility (rSASA)
- 0.32
- Highest tissue expression
- 2.1 nTPM
Expression across tissuesHPA
Tissue
- ovary: 2.1 nTPM
- testis: 2.1 nTPM
- adipose tissue: 1.2 nTPM
- adrenal gland: 0.8 nTPM
- breast: 0.7 nTPM
- thyroid gland: 0.6 nTPM
Single-cell type
- adipocytes: 3.4 nCPM
- corticotrophs: 0.5 nCPM
- pituicytes/fscs: 0.3 nCPM
- fibroblasts: 0.2 nCPM
- hofbauer cells: 0.2 nCPM
- innate lymphoid cells: 0.2 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- medulla oblongata: 6.1 nTPM
- spinal cord: 3.1 nTPM
- white matter: 2.8 nTPM
- pons: 1.9 nTPM
- cerebellum: 1.7 nTPM
- hypothalamus: 1.7 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about LHCGR.
Disease | AllUniProt
Conditions LHCGR is implicated in, by any mechanism.
- Familial male precocious puberty (FMPP) MIM:176410
- Luteinizing hormone resistance (LHR) MIM:238320
Disease | GeneticClinVar
55 pathogenic / likely-pathogenic of 317 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Leydig cell agenesis
- Gonadotropin-independent familial sexual precocity
- Luteinizing hormone resistance, female
- LHCGR-related disorder
- Leydig cell hypoplasia, type II
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.89
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.16
- DepMap mean gene effect
- 0.08
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- adenylate cyclase-activating G protein-coupled receptor signaling pathway
- cellular response to gonadotropin stimulus
- cellular response to luteinizing hormone stimulus
- cognition
- development of secondary male sexual characteristics
- G protein-coupled receptor signaling pathway
- G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger
- hormone-mediated signaling pathway
- luteinizing hormone signaling pathway
- male genitalia development
- male gonad development
- ovarian follicle development
- ovulation cycle process
- phospholipase C-activating G protein-coupled receptor signaling pathway
- positive regulation of inositol trisphosphate biosynthetic process
- seminiferous tubule development
- spermatogenesis
- uterus development
- regulation of steroid hormone biosynthetic process
Molecular functions
- G protein-coupled peptide receptor activity
- choriogonadotropin hormone binding
- choriogonadotropin hormone receptor activity
- luteinizing hormone receptor activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of LHCGR in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads LHCGR as an antibody target. Whether an autoantibody or antibody against LHCGR could matter depends on whether native LHCGR is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
LHCGR is annotated at the cell surface, where native LHCGR is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label LHCGR as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...